Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness (Immunogenicity) and Safety of GC1107 Administered Intramuscularly in Healthy Adults

Trial Profile

Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness (Immunogenicity) and Safety of GC1107 Administered Intramuscularly in Healthy Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs GC 1107 (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 17 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top